VIVE - Viveve to get US patent for technology to treat female stress urinary incontinence

• Viveve Medical ( NASDAQ: VIVE ) stock rose ~4% on Oct. 4 after the company said that the U.S. Patent and Trademark Office will issue a patent — application no. 16/454,578 — covering Viveve's dual-energy technology to treat female stress urinary incontinence (SUI).
• The dual-energy technology has shown to activate fibroblasts and initiate collagen formation in tissue in a non-invasive, painless procedure. When applied to the areas surrounding the urethra, it may improve the function of connective tissues, improve vaginal structural integrity, and reduce urethral hypermobility, a cause of SUI in women, the company said in an Oct. 4 press release.
• "We look forward to completing our pivotal PURSUIT clinical trial, which may support a new U.S. indication for the treatment of mild-moderate SUI in women if the results are positive," said Viveve's CEO Scott Durbin.

For further details see: